Trials / Unknown
UnknownNCT04651933
A Training Set for the HRD Model in EOC
A Training Set for the Homologous Recombination Deficiency Scoring Model With Loss of Heterozygosity Status in Epithelial Ovarian Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.
Conditions
- Epithelial Ovarian Cancer
- BRCA Mutation
- Loss of Heterozygosity
- Prognosis
- Platinum Resistance
- Homologous Recombination Deficiency
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Homologous recombination deficiency model | A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) |
Timeline
- Start date
- 2020-11-26
- Primary completion
- 2022-11-26
- Completion
- 2022-11-26
- First posted
- 2020-12-03
- Last updated
- 2020-12-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04651933. Inclusion in this directory is not an endorsement.